Telmisartan Shows Organoprotection and Reduces the Incidence of Adverse Cardiovascular Outcomes in Addition to the Antihypertensive Effect

HYPERTENSION
doi 10.22141/2224-1485.4.48.2016.76998
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Publishing House Zaslavsky

Related search

Antihypertensive Medication Exposure and Cardiovascular Outcomes in Hemodialysis Patients

American Journal of Nephrology
Nephrology
2014English

Follow-Up Shows No Adverse Outcomes of CNEP in Neonates

BMJ
2006English

The Incidence of Isolated Single Umbilical Artery in Twins and Adverse Pregnancy Outcomes

Prenatal Diagnosis
GynecologyGeneticsObstetrics
2013English

Living in Food Deserts and Adverse Cardiovascular Outcomes in Patients With Cardiovascular Disease

Journal of the American Heart Association
Cardiovascular MedicineCardiology
2019English

Incidence of Adverse Cardiovascular Events in Adults Following Drug Overdose

Academic Emergency Medicine
MedicineEmergency Medicine
2012English

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial†

Journal of Clinical Lipidology
Internal MedicineNutritionCardiologyEndocrinologyCardiovascular MedicineDieteticsMetabolismDiabetes
2019English

An Improved Synthesis of Telmisartan: An Antihypertensive Drug

Arkivoc
Organic Chemistry
2009English

Cardiovascular Protective Effect of Metformin and Telmisartan: Reduction of PARP1 Activity via the AMPK-PARP1 Cascade

PLoS ONE
Multidisciplinary
2016English

The Effects of Angiotensinogen Gene Polymorphisms on Cardiovascular Disease Outcomes During Antihypertensive Treatment in the GenHAT Study

Frontiers in Pharmacology
Pharmacology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy